Introduction to
FFPE Blocks for Pharma Companies
High-Quality FFPE Blocks for Pharmaceutical Oncology Research
Pharmaceutical oncology programs require biospecimens that can support reproducible biomarker discovery, translational research, assay development and therapeutic development. Research-grade FFPE blocks provide access to preserved tumor tissue that can be evaluated using histology, immunohistochemistry, FISH, PCR, NGS and other molecular techniques.
Carefully selected FFPE specimens can be supplied according to indication, histological subtype, tumor percentage, disease stage, treatment history, biomarker status and other study-specific criteria. For pharmaceutical researchers, access to well-documented archival tumor material can accelerate feasibility studies and reduce the time required to identify suitable cases. FFPE blocks may also be linked with pathology information, clinical characteristics and available molecular testing results, allowing investigators to build more precisely defined research cohorts. Customized sourcing can support studies across lung, breast, colorectal, pancreatic, ovarian, prostate, renal, head and neck and other malignancies.
Clinically Annotated FFPE Tumor Blocks for Drug Development
Clinical annotation increases the research value of FFPE tumor material by allowing pharmaceutical teams to investigate how molecular and pathological characteristics relate to disease behavior, therapeutic exposure and clinical outcomes. Depending on availability and study requirements, FFPE blocks can be associated with information such as diagnosis, histological subtype, stage, grade, age, sex, collection date, treatment history, recurrence, metastatic status and selected outcome variables. This enables researchers to build targeted cohorts for drug-response investigations, retrospective biomarker studies and companion diagnostic development.
Â
Clinical annotation is particularly important when research programs require specific patient subpopulations rather than broad tumor categories. By combining FFPE material with structured clinical and pathology data, pharmaceutical companies can improve cohort stratification and identify samples that match protocol-defined inclusion and exclusion criteria. Such biospecimens can support discovery research, translational validation, assay optimization and retrospective exploratory studies.
Molecularly Characterized FFPE Samples for Biomarker Discovery
Molecularly characterized FFPE samples are valuable for pharmaceutical companies developing targeted therapies, biomarker strategies and precision-oncology programs. FFPE specimens may be selected based on known genomic alterations, protein-expression patterns or previously generated molecular results. Depending on the available dataset, characterization can include DNA sequencing, RNA analysis, gene-expression information, mutation status, amplification status, fusion detection, immunohistochemistry or other orthogonal testing methods.
These samples allow research teams to enrich studies for molecular subgroups rather than screening large numbers of uncharacterized specimens. Molecularly defined cohorts can be useful for analytical validation, algorithm development, biomarker assessment and translational research focused on specific therapeutic mechanisms. When combined with pathology review and tumor-content assessment, characterized FFPE blocks can help investigators select specimens with sufficient material and biological relevance for downstream testing.
Custom FFPE Cohorts for Preclinical and Translational Studies
Pharmaceutical research programs often require FFPE cohorts built around highly specific study criteria rather than generic tumor collections. Custom FFPE sourcing enables investigators to define indication, histology, disease stage, grade, biomarker expression, mutation status, treatment exposure, sample age, tumor percentage and other important variables. Cohorts can be developed for feasibility studies, biomarker validation, assay development, retrospective translational studies and drug-development programs.
Pathology review can help confirm diagnosis and assess tumor adequacy before specimens are selected for downstream research. Where available, FFPE blocks may also be linked with H&E images, immunohistochemistry results, molecular data and clinical annotations. This approach gives pharmaceutical teams greater flexibility when designing studies around targeted patient populations. Customized FFPE cohorts are particularly useful for oncology programs investigating resistance mechanisms, response biomarkers, tumor heterogeneity and potential companion diagnostic strategies.
General Questions
Frequent Asked Questions!!
FFPE blocks for genomics are formalin-fixed, paraffin-embedded tissue samples used for DNA, RNA, and biomarker analysis. They are widely used in cancer genomics, molecular pathology, translational research, and retrospective studies.
FFPE tissue blocks are valuable because they preserve tissue architecture and molecular material for long-term storage. Researchers can use them for sequencing, mutation analysis, biomarker discovery, and validation studies.
Yes. DNA can be extracted from FFPE blocks using validated extraction kits and optimized laboratory protocols. DNA quality depends on fixation time, block age, tissue type, tumor content, and storage conditions.
Yes. RNA can be extracted from FFPE tissue, although it is often fragmented because of formalin fixation. Specialized FFPE RNA extraction methods can provide material suitable for targeted RNA sequencing, gene expression studies, and fusion analysis.
Yes. High-quality FFPE blocks are commonly used for next-generation sequencing, including targeted sequencing panels, whole-exome sequencing, RNA sequencing, and selected whole-genome applications.
Tumor content requirements depend on the study design and testing method. Many molecular and NGS studies require at least 20% tumor content, while some projects may require 30%, 50%, or higher tumor percentage. Pathologist review can be performed to confirm tumor content before shipment
FFPE blocks can support mutation testing, copy number analysis, gene fusion detection, microsatellite instability testing, tumor mutational burden analysis, methylation studies, and targeted DNA or RNA sequencing.
Yes. FFPE cancer tissue blocks are extensively used to study genomic alterations in lung, breast, colorectal, prostate, ovarian, pancreatic, liver, kidney, and other tumor types.
Researchers can purchase FFPE blocks from qualified biospecimen suppliers, biobanks, pathology laboratories, hospitals, and research networks that provide ethically sourced and clinically annotated human tissue samples.
Researchers should confirm diagnosis, tissue type, tumor percentage, necrosis percentage, fixation details, block age, specimen size, available clinical data, pathology review, consent status, and intended research-use permissions.
Yes. Clinically annotated FFPE blocks may include donor age, sex, diagnosis, grade, stage, TNM classification, treatment history, pathology report, mutation status, and clinical outcome data.